Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 1 epsHost
Recent guests
Recent episodes
Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive
Apr 30, 2026
42m 52s
The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel
Apr 15, 2026
Unknown duration
Physics, Free Energy, & Drug Discovery: Inside Schrödinger's Computational Platform
Apr 1, 2026
Unknown duration
AI in biotech: separating hype from reality with Ben Locwin
Mar 11, 2026
Unknown duration
3D Printing Therapeutics at Scale with Aprecia Pharmaceuticals
Feb 25, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/30/26 | Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive✨ | data infrastructurebiotech+3 | Jesse Johnson | MerelogicGoogle | — | data strategybiotech labs+3 | — | 42m 52s | |
| 4/15/26 | The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel | In this episode of Data in Biotech, host Ross Katz sits down with Kevin Brown, co-founder of Standard BioModel, to explore one of the most ambitious projects in biomedical AI, building a multimodal foundation model that represents the full complexity of a patient across time. Drawing on a career spanning brain-computer interfaces, computer-aided diagnosis at Siemens Healthineers, and oncology data science at Bristol Myers Squibb, Kevin shares the scientific and philosophical journey that led him to a single conviction: a patient is not a document. Rather than reducing a patient to clinical notes, ICD-10 codes, or isolated test results, Standard BioModel's approach maps every available modality - CT imaging, digital pathology, genomics, EKGs, longitudinal EHR data - into a shared latent space, and models how that patient moves through time. The result is a framework designed not just for prediction, but for counterfactual reasoning, clinical trial matching, and personalized intervention, with open-source models already being validated across leading academic medical centers. What you’ll learn in this episode: >> Why reducing a patient to text - clinical notes, radiology reports, genomic assay summaries - and how mapping multimodal data into a shared latent embedding space preserves information that never makes it into the written record >> How Standard BioModel's temporal architecture models patients as trajectories through an abstract embedding space rather than static snapshots, enabling counterfactual reasoning about the likely impact of interventions on a patient's future health trajectory >> Why no single foundation model can own every clinical vertical and how building a highly generalizable base model that facilitates downstream fine-tuning is a more defensible and scalable strategy than building narrow, application-specific models >> How the model handles missing modalities in real-world clinical settings, and why the architecture is designed to function effectively even when not every data type is available for every patient >> Why Standard BioModel has chosen to open-source its models and why broad, institution-specific validation across diverse patient populations is not just a scientific priority, but a prerequisite for trustworthy clinical AI Meet our guest: Kevin Brown is the Founder and CEO of Standard Model Biomedicine, where he builds foundation models for biomedicine. He previously led AI work as Director of Artificial Intelligence at SimBioSys, and held data science and applied ML roles at Bristol Myers Squibb and Siemens Healthineers. With a neuroscience research background from New York University, Kevin’s work spans generative AI and machine learning for biomedical and medical imaging applications. Connect with Kevin Brown on LinkedIn About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 4/1/26 | Physics, Free Energy, & Drug Discovery: Inside Schrödinger's Computational Platform | In this episode of Data in Biotech, Ross Katz sits down with Robert Abel, Chief Scientific Officer of the Platform at Schrödinger, to explore how physics-based computational modeling is transforming drug discovery. Robert unpacks why machine learning alone isn't enough to navigate the vast complexity of chemical space - an estimated at 10⁶⁰ possible drug-like molecules - and how integrating atomistic simulations with ML creates a more accurate, reliable, and scalable approach to identifying viable drug candidates. From free energy perturbation calculations to generative AI, Robert offers a rare inside look at how Schrödinger's technology platform is accelerating the path from target identification to clinical candidate and where the field is headed next. What you’ll learn in this episode: >> Why chemical space (~10⁶⁰ molecules) makes purely data-driven ML approaches fundamentally insufficient for drug discovery, and how physics-based sampling solves the training data problem >> How free energy perturbation (FEP) calculations enable quantitative prediction of protein-ligand binding affinities at near-experimental accuracy (~1.2 kcal/mol RMSE) >> How Schrödinger's active learning framework combines physics-based simulations and ML to triage billions of candidate molecules before committing to wet lab synthesis >> Why Schrödinger operates across three business lines; software licensing, collaborative programs, and proprietary drug discovery and how each strengthens the underlying technology platform >> Where the next frontiers lie: routine anti-target selectivity profiling, retrosynthetic AI integration, and the expanding role of generative ML in de novo molecular design Meet our guest: Robert Abel is Chief Scientific Officer, Platform at Schrödinger, where he helps lead the scientific direction behind computational approaches that support modern drug discovery and molecular design. With a PhD in Chemical Physics from Columbia University and a deep background in computational chemistry, he has held multiple senior science leadership roles at Schrödinger, guiding teams that build and scale scientific methods into production-grade platforms used across research and industry. Connect with Robert Abel on LinkedIn About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 3/11/26 | AI in biotech: separating hype from reality with Ben Locwin | In this episode of Data in Biotech, host Ross Katz sits down with Ben Locwin, Vice President at Reliant Life Sciences, to explore the evolving landscape of artificial intelligence in biotechnology. Join us as we discuss why nearly every biotech claims to use AI but few actually do, examine successful applications like AlphaFold, and explore the challenges of implementing AI across drug development, manufacturing, and regulatory processes. Ben shares insights on maintaining healthy skepticism, understanding data provenance, and looking ahead to what this year may bring for AI in life sciences. What you’ll learn in this episode: >> The AI hype problem in biotech and why most companies claim to use AI but few actually do. >> AlphaFold as the gold standard and how DeepMind's protein structure prediction model represents the most successful application of AI in biotech >> Data quality over algorithmic sophistication and the critical importance of data provenance, examining primary sources, and understanding that data quality matters more than the complexity of the AI model >> The balance between optimism and evidence-based decision-making, distinguishing between sophisticated AI and advanced statistical modeling Meet our guest: Ben Locwin is a healthcare and life sciences executive and medical scientist known for helping bring pharmaceuticals, vaccines, and medical devices to market faster and with higher quality. A TEDx speaker and seasoned leader, he’s worked across major biotech hubs and has deep expertise in global regulatory pathways, having collaborated with the FDA, EMA, MHRA, PMDA, and more. Connect with Ben Locwin on LinkedIn About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 2/25/26 | 3D Printing Therapeutics at Scale with Aprecia Pharmaceuticals | In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world’s first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 2/11/26 | Success-Driven Drug Discovery with OpenBench CEO James Yoder | In this episode of Data in Biotech, host Ross Katz sits down with James Yoder, Founder and CEO of OpenBench, to unpack a radical new approach to early-stage drug discovery. James shares how OpenBench's "success-driven" model shifts risk away from biotech partners by only charging for validated hits. They dive deep into computational screening, molecular modeling, and the company's evolving tech stack that's making hit discovery smarter and more accessible. Discover how data, AI, and strategic collaboration are redefining biotech R&D. What you'll learn in this episode: >> Why OpenBench moved away from SaaS to a success-based service model >> How their computational platform predicts binding affinity and screens trillions of compounds >> The role of data flywheels and ML in improving drug discovery success rates >> Real-world case studies from biotech collaborations >> How OpenBench evaluates druggable targets in one week Meet our guest James Yoder is the Founder and CEO of OpenBench. With a background in statistics, data science, and applied machine learning, he leads OpenBench's mission to deliver validated drug discovery hits through computational innovation and a success-driven business model. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with James Yoder on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 1/29/26 | Brant Peterson on Valo Health’s patient-first approach to drug discovery | Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson’s, this episode dives deep into a patient-first, data-driven approach to biomedical innovation. What You'll Learn in This Episode: >> How Valo Health uses real-world evidence and EHR data to prioritize drug targets earlier in the development pipeline. >> Why integrating wet lab experiments and causal DAGs accelerates therapeutic validation. >> The importance of genetic pleiotropy and Mendelian randomization in refining disease hypotheses. >> How Valo Health identifies high-impact patient subgroups in neurodegenerative diseases like Parkinson’s and Alzheimer’s. >> Where machine learning models succeed and fall short, in uncovering mechanisms of disease from sparse longitudinal data. Meet Our Guest Brant Peterson is Vice President & Fellow in Data Science at Valo Health. He brings deep expertise in genetics, computational biology, and biomedical innovation. Formerly a Distinguished Data Scientist at Valo and Computational Biologist at Novartis, Brant focuses on leveraging patient-centric data to drive causal discovery in drug development. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Brant Peterson on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 1/14/26 | Inside Dash Bio’s productized CRO model with Ander Tallet | Ander Tallet, co-founder and COO of Dash Bio and CEO of DigitalRadius, joins Ross Katz to discuss transforming the traditional CRO model through automation, transparency, and productization. Drawing on deep experience from Moderna, Science Exchange, and his leadership roles in digital transformation, Ander shares how Dash Bio is slashing turnaround times, improving data quality, and simplifying procurement for biotech companies. This episode unpacks the future of CRO services, strategic procurement, and the power of operational innovation in biotech. What you'll learn in this episode: >> Why traditional CRO models hinder speed and transparency in biotech >> How Dash Bio delivers 90% faster turnaround through automation >> What productizing CRO services really means for the customer experience >> How regulatory requirements shape innovation in clinical bioanalysis >> Why investor buy-in requires solving real, painful problems in biotech Meet our guest Ander Tallett is the co-founder and COO of Dash Bio and the CEO of DigitalRadius, where he leads digital transformation initiatives as one of the largest Smartsheet partners in the ecosystem. He previously served as Chief Strategy Officer at Science Exchange and co-founded Block Mill Capital, a B2B SaaS-focused investment fund shaped by his experience evaluating and implementing more than 100 SaaS platforms. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with Ander Tallet on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/31/25 | From discovery to delivery: AI’s impact on nanomedicine | In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space. What you'll learn in this episode: >> How AI and ML reduce costs and increase success rates in nanomedicine development. >> Key challenges in nano drug delivery and how machine learning helps overcome them. >> How HTD Biosystems' iFormulate platform speeds up formulation with predictive modeling. >> How wearables and real-time data are reshaping clinical trial design. >> The future of personalized and automated drug delivery systems. Meet our guest Mitra Mosharraf is the Chief Scientific Officer at HTD Biosystems and co-founder of Engimata Inc. With 20+ years of experience, she leads innovation in biologics, nanomedicine, and lipid-based delivery systems. Mitra is a recognized thought leader in pharmaceutical sciences. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Mitra Mosharraf on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/26/25 | Jaidev Chakka on building the future of bioprinted medicine | In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine. What you'll learn in this episode: >> How 3D printing is enabling customized bone scaffolds and regenerative therapies >> The role of AI in optimizing pharmaceutical 3D printing parameters >> How organoids can act as micro-organs for testing and computation >> The promise and challenge of personalized, on-demand drug manufacturing >> Why collaboration between data scientists and biopharma researchers is critical Meet our guest LR Jaidev Chakka is a Principal Scientist at the University of Mississippi School of Pharmacy, pioneering 3D bioprinting, drug delivery, and organoid research to revolutionize patient care and pharma manufacturing. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jaidev Chakka on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/22/25 | From screening to IND: How Veloxity accelerates critical drug decisions | In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients >> The benefits and challenges of working with peptides and GLP-1 receptor agonists >> How the SCIEX 8600 enhances detection of low-concentration analytes Meet our guests Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development. Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Isa Kupke on LinkedIn Connect with Callie Celichowski on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/15/25 | Revolutionizing bioanalysis with high-resolution mass spec | In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/3/25 | Mastering solubility and stability in drug development with Serán BioScience | In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren’t yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he’s especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/26/25 | Applying ML/AI to Drug Development with Anil Kane | Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher’s ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/20/25 | Streamlining bioanalytical workflows with Watson LIMS and Thermo Fisher | In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow. >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/5/25 | Scaling AI infra in biotech with Saturn Cloud and Nebius | Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi on LinkedIn Connect with IIya Burkov on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 10/22/25 | The Future of Co-Folding and Federated Learning with Apheris | Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery. What You'll Learn in This Episode >> Why federated learning is a game-changer for pharma data sharing and AI-driven research >> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge >> The role of structural benchmarking in model development and validation >> How Apheris enables privacy-preserving collaboration between major pharma players >>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy Meet Our Guest Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Robin Roehm on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 10/1/25 | Automating biopharma knowledge work with Convoke | What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure. What You'll Learn in This Episode: >> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making >> Why structured outputs and semantic layers are key to high-quality AI-driven insights >> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation >> How feedback loops and model evaluations drive product reliability and user trust >> The future of AI in biotech: continuous decision-making and multimodal intelligence Meet Our Guests Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions. Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Alex Telford on LinkedIn Connect with Maged Ahmed on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 9/17/25 | How Eli Lilly’s new platform TuneLab codevelops AI models with biotech | Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D. What You'll Learn in This Episode: >> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data >> What federated learning means for IP protection and collaborative data sharing in biotech >> Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability >> How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution >> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development Meet Our Guest Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Aliza Apple on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 9/3/25 | Inside Merck's Computational Biology Approach with Jesper Ryge | In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 8/20/25 | Where Biotech Innovation Really Happens: 50th Episode Special with Wolfgang Halter, Jacob Oppenheim, and Dave Johnson | To mark our 50th episode, host Ross Katz brings back three visionary leaders—Dave Johnson (Dash Bio), Wolfgang Halter (Merck Life Science), and Jacob Oppenheim (RAVen)—together for a reflection on the evolution of biotech. They unpack the realities behind AI hype, the future of data-driven innovation, and what’s really changing in drug development. What You'll Learn in This Episode: >> Where real innovation is emerging across startups, big tech, and academia >> The biggest misconceptions about data in biotech—and why they persist >> What it takes to build trust in AI-powered biotech tools >> Why progress in biotech depends as much on execution as it does on breakthroughs >> How industry veterans see the future of automation, regulation, and global competition Meet Our Guests Dave Johnson is CEO and Co-Founder of Dash Bio and former Chief Data & AI Officer at Moderna. He’s pioneering automation in clinical bioanalysis to accelerate drug development. Wolfgang Halter leads Data Science at Merck Life Science, developing tools like BayBE to optimize R&D through smarter data modeling and open-source innovation. Jacob Oppenheim is a Venture Partner at RAVen and co-founder of Fresnel. With a PhD in Biological Physics, he champions the transition to digital-native biopharma. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Dave Johnson on LinkedIn Connect with Wolfgang Halter on LinkedInConnect with Jacob Oppenheim on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 7/31/25 | How BioRaptor is Modernizing Bioprocessing Workflows | In this episode of Data in Biotech, Yaron David, CTO and Co-Founder of BioRaptor, joins host Ross Katz to explore how biotech companies can gain a holistic view of bioprocessing through real-time data integration, visualization, and modeling. Learn how BioRaptor’s full-stack platform helps scientists replace clunky spreadsheets with actionable insights—accelerating experiments and optimizing yields. What You'll Learn in This Episode: >> Why Excel is holding back innovation in bioprocessing labs >> How BioRaptor enables holistic bioprocess understanding across experiments >> The role of virtual sensors in enhancing real-time data visibility >> How BioRaptor drives ROI by onboarding customers in weeks, not months >> The difference between operational and optimization AI in biotech Meet Our Guest Yaron David is CTO and Co-Founder of BioRaptor, an AI-powered analytics platform transforming bioprocess data into scientific insights. With an MD and PhD in neuroscience, he blends medical, software, and startup experience to revolutionize data infrastructure for biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about BioRaptorConnect with Yaron David on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 7/11/25 | Modernizing Clinical Data Analysis with Jesse Paquette | In this episode of Data in Biotech, Jesse Paquette, co-founder and Chief Science Officer of Tag.bio, joins Ross Katz to explore how data mesh architecture and FAIR data principles are transforming clinical and research workflows in life sciences. From harmonizing legacy systems to enabling AI-readiness, Jesse shares how Tag.bio empowers domain experts to make data-driven decisions faster and more effectively. What You'll Learn in This Episode: >> How Tag.bio leverages data mesh and FAIR principles to democratize biomedical data access. >> The challenges biotech firms face with legacy infrastructure and clinical trial data. >> The importance of harmonized, version-controlled data products in AI-driven research. >> Why smaller pharma and life sciences firms benefit most from Tag.bio’s agile platform. Meet Our Guest Jesse Paquette is the co-founder and Chief Science Officer of Tag.bio, where he leads scientific strategy for AI-powered analytics. With over two decades in life sciences, he specializes in building tools that help researchers interpret complex biomedical data independently. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Tag.bioConnect with Jesse Parquette on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 6/25/25 | Building Scalable Data Platforms for Spatial Biology with Kenny Workman of LatchBio | In this episode of Data in Biotech, Ross Katz sits down with Kenny Workman, co-founder and CTO of LatchBio, to unpack how biotech’s data infrastructure must evolve to meet the demands of next-gen assays. From scalable workflows to high-performance visualization tools, Kenny breaks down the shift from traditional biotech to a future defined by data-driven research and agile cloud platforms. What You'll Learn in This Episode: Why spatial biology and high-throughput assays require new data infrastructure strategiesHow LatchBio’s five core components streamline molecular data processingThe challenges of selling into biotech vs. solution providers and the strategic pivot LatchBio made to address thisHow large language models are revolutionizing public data curation for biotechsWhy scientific innovation demands better tech adoption across the industry Meet Our Guest Kenny Workman is co-founder and CTO of LatchBio, a company transforming biological data infrastructure. A UC Berkeley alum, Kenny brings deep expertise in bioengineering, machine learning, and cloud systems. He was named to Forbes' 2023 "30 Under 30" list for his contributions to computational biology. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Latch BioConnect with Kenny Workman on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 6/11/25 | Solving Chronic Disease with Life Insurance and Data Featuring Jeremy Shane | Entrepreneur Jeremy Shane joins host Ross Katz to discuss Life for Health, a revolutionary framework aiming to tackle chronic disease through the integration of life insurance, longitudinal data, and preventative care. From drug discovery feedback loops to outcomes-based pricing, Shane outlines a bold new path for biotech and healthcare convergence. What You'll Learn in This Episode: Why today's healthcare system fails chronic disease patients and how Life for Health aims to fix it.How longitudinal data and life insurance can realign healthcare incentives for better outcomes.The economic logic behind outcomes-based annuity pricing for breakthrough drugs like GLP-1s.What biotech companies gain from a proactive, participant-driven health model.How clinical trials could transform through pre-qualified data-rich populations. Meet Our Guest Jeremy Shane, Venture Partner at NextGen Venture Partners, is a healthcare innovator focused on chronic disease. With leadership experience at HealthCentral, WebMD, and 2U, he now pioneers Life for Health, blending life insurance with preventative care to realign incentives and extend health span. Life for Health, the book, will be released in July 2025. To learn more about Life For Health or get involved, go to www.lifeforhealth.com About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jeremy Shane on LinkedIn or on Twitter @jeremylshane Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
Showing 25 of 70
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
7 placements across 7 markets.
Chart Positions
7 placements across 7 markets.